Mechanism of Action: Platelet-derived Growth Factor alpha Receptor Inhibitors
✉ Email this page to a colleague
Drugs with Mechanism of Action: Platelet-derived Growth Factor alpha Receptor Inhibitors
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Deciphera Pharms | QINLOCK | ripretinib | TABLET;ORAL | 213973-001 | May 15, 2020 | RX | Yes | Yes | 11,344,536 | ⤷ Subscribe | ⤷ Subscribe | ||||
Deciphera Pharms | QINLOCK | ripretinib | TABLET;ORAL | 213973-001 | May 15, 2020 | RX | Yes | Yes | 11,850,241 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
Deciphera Pharms | QINLOCK | ripretinib | TABLET;ORAL | 213973-001 | May 15, 2020 | RX | Yes | Yes | 12,023,326 | ⤷ Subscribe | ⤷ Subscribe | ||||
Deciphera Pharms | QINLOCK | ripretinib | TABLET;ORAL | 213973-001 | May 15, 2020 | RX | Yes | Yes | 12,059,410 | ⤷ Subscribe | ⤷ Subscribe | ||||
Deciphera Pharms | QINLOCK | ripretinib | TABLET;ORAL | 213973-001 | May 15, 2020 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
Deciphera Pharms | QINLOCK | ripretinib | TABLET;ORAL | 213973-001 | May 15, 2020 | RX | Yes | Yes | 11,266,635 | ⤷ Subscribe | ⤷ Subscribe | ||||
Deciphera Pharms | QINLOCK | ripretinib | TABLET;ORAL | 213973-001 | May 15, 2020 | RX | Yes | Yes | 11,395,818 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |